You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新諾威(300765.SZ):控股子公司與Radiance Biopharma公司簽署SYS6005獨家合作協議
格隆匯 02-19 08:50

格隆匯2月19日丨新諾威(300765.SZ)公佈,公司的控股子公司石藥集團巨石生物製藥有限公司(以下簡稱"巨石生物")與Radiance Biopharma, Inc.(以下簡稱"Radiance Biopharma")達成協議,Radiance Biopharma將獲得巨石生物自主研發的重組抗人類受體酪氨酸激酶樣孤兒受體1(ROR1)抗體偶聯藥物SYS6005(以下簡稱"SYS6005")項目在一定區域範圍內的開發和商業化等權利。

據悉,巨石生物研發的SYS6005是一款單克隆抗體偶聯藥物,可與腫瘤表面的特異性受體結合,通過內吞作用進入細胞並釋放毒素,達到殺傷腫瘤細胞的作用。SYS6005按照治療用生物製品1類申報,獲批的適應症爲晚期腫瘤,預計適用於治療血液腫瘤、卵巢癌、非小細胞肺癌等。

SYS6005採用巨石生物的酶催化定點抗體偶聯技術,通過穩定的連接技術可有效降低有絲分裂抑制劑MMAE的全身暴露量,靶向性導向ROR1表達的癌細胞並釋放毒素,進而降低藥物相關副作用。與正常組織相比,ROR1在多種血液惡性腫瘤和實體腫瘤中高度表達,其表達與疾病進展和治療反應密切相關,使ROR1成爲抗癌藥物開發中一個具有吸引力的治療靶點。SYS6005的設計具有均勻的DAR分佈、更高穩定性的專有連接子及較低的藥物-抗體比率,以提高血液穩定性和腫瘤部位特異性藥物釋放,從而獲得更好的安全性和療效。

Radiance Biopharma專注於開發基於抗體的癌症治療藥物管線,包括單特異性和雙特異性抗體偶聯藥物(ADC),以治療癌症並解決其他未滿足的醫療需求。經營地位於美國馬薩諸塞州波士頓。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account